Genome-wide CRISPR screening reveals novel therapeutic targets in RIT1-driven lung cancer [0.03%]
基于CRISPR的基因敲除筛选发现RIT1驱动的肺癌新的治疗靶点
Amanda K Riley,Alice H Berger
Amanda K Riley
In recent work, we performed CRISPR/Cas9 screening in RIT1 (Ras-like in all tissues)-mutant cancer cells. We found that RIT1-mutant cells are vulnerable to loss of mitotic regulators, and mutant RIT1 synergizes with YAP1 (yes-associated pro...
SPF45/RBM17-dependent splicing and multidrug resistance to cancer chemotherapy [0.03%]
SPF45/RBM17依赖的剪接及癌症化疗耐药性
Kazuhiro Fukumura,Julian P Venables,Akila Mayeda
Kazuhiro Fukumura
The early splicing complex A occupies at least eighty nucleotides of intron, in which U2AF covers the polypyrimidine tract. SPF45 (RBM17) functionally substitutes for U2AF on a subset of short introns. Since SPF45 expression confers resista...
The perfect PTEN - transcriptional regulation by PTEN dictates sarcoma identity [0.03%]
PTEN的完美平衡——PTEN转录调控决定肉瘤身份
Casey G Langdon,Mark E Hatley
Casey G Langdon
Fusion-negative rhabdomyosarcoma (FN-RMS) is molecularly heterogeneous with few universal alterations except for Phosphatase and tensin homolog (PTEN) promoter hypermethylation. We demonstrate that losing Pten in FN-RMS engages an aberrant ...
Interdisciplinary team science to understand and intercept rare cancers [0.03%]
学科交叉团队科学研究罕见癌症的理解与阻击
Stefan Fröhling
Stefan Fröhling
For most rare cancers, precision oncology approaches are not established because these entities are poorly understood and their investigation requires the collaboration of many centers. The MASTER precision oncology network demonstrates tha...
Sunghoon Kim,Andrew Wolfe,Sung Eun Kim
Sunghoon Kim
Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the...
Caiyun Liu,Xinjian Li
Caiyun Liu
How cancer cells absorb enough glucose to support their rapid growth is poorly understood. We have recently demonstrated that palmitoyl transferase DHHC9 palmitoylates glucose transporter GLUT1 at Cys207 to maintain GLUT1 plasma membrane lo...
ZNF768: controlling cellular senescence and proliferation with ten fingers [0.03%]
锌指基因ZNF768用十个手指调控细胞衰老和增殖
Romain Villot,Audrey Poirier,Romain Devillers et al.
Romain Villot et al.
We recently identified Zinc-finger protein 768 (ZNF768) as a novel transcription factor controlling cell fate decision downstream of Rat sarcoma virus (RAS). We showed that ZNF768 depletion impairs cell cycle progression and triggers cellul...
Cell demise inhibited: Unexpected liaisons between mitochondria and IκΒα [0.03%]
细胞死亡受抑：线粒体和IκBα的意外联系
Evangelos Pazarentzos
Evangelos Pazarentzos
IκΒα (the protein product of NFKBIA gene) has widely been considered a pro- apoptotic factor due to its ability to inhibit the anti-apoptotic transcription factor NFκB. Our findings indicate that IκΒα also exerts a strong anti-apopto...
A therapeutic window for preventive therapy in NF1-associated optic pathway glioma [0.03%]
NF1相关视路胶质瘤预防性治疗的治疗窗口期研究
Yuan Zhu,Wang Zheng,Emmanuelle S Jecrois et al.
Yuan Zhu et al.
Pediatric low-grade gliomas (pLGGs) are almost universally driven by abnormal activation of RAS-mediated MEK-ERK/MAPK signaling pathway. pLGGs predominantly occur in children, suggesting that they originate in an ERK-dependent neural stem/p...
Aurora A and Mcl-1: new potential treatment targets in antiestrogen-resistant breast cancer [0.03%]
乳腺癌中抗雌激素耐药的新治疗靶点Aurora A和Mcl-1
Christina W Yde
Christina W Yde
Antiestrogen resistance is a major clinical limitation in treatment of breast cancer. We have recently reported that Aurora A and Mcl-1 (myeloid cell leukemia 1) are potential novel treatment targets in antiestrogen-resistant breast cancer ...